What Retatrutide and Foundayo Mean for Obesity Treatment in 20262028 The approval of Foundayo marks the beginning of a new era for obesity medicine
Still, BMI remains the standard
The National Institute for Health and Care Excellence (NICE) provides guidance on the use of GLP-1 receptor agonists in guideline NG28, recommending them for type 2 diabetes in specific contexts, such as when other therapies have proven inadequate, particularly in people with higher BMI or cardiovascular risk factors
Huang F, Zhang L, Song X, Xu H, Wang F, Zhou L, et al
The most common side effects were nausea, diarrhea, and fatigue